3-(2-甲氧基甲基-吡咯烷-1-羰基)-5-甲基-苯甲酸 | 1042903-72-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-(2-甲氧基甲基-吡咯烷-1-羰基)-5-甲基-苯甲酸
• 英文名称: 3-(2-methoxymethyl-pyrrolidine-1-carbonyl)-5-methyl-benzoic acid
• 英文别名: 3-[(2R)-2-(methoxymethyl)pyrrolidine-1-carbonyl]-5-methylbenzoic acid
• CAS: 1042903-72-9
• 化学式: C₁₅H₁₉NO₄
• 分子量: 277.32
• InChiKey: ZUEZXSWUSBCRRT-CYBMUJFWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  66.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-(2-甲氧基甲基-吡咯烷-1-羰基)-5-甲基-苯甲酸 、 tert-butyl (R)-2-((1S,2S)-2-amino-3-(3,5-difluorophenyl)-1-hydroxypropyl)-4-benzylpiperazine-1-carboxylate 在 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 作用下， 生成 tert-butyl (2R)-4-benzyl-2-[(1S,2S)-3-(3,5-difluorophenyl)-1-hydroxy-2-[[3-[(2R)-2-(methoxymethyl)pyrrolidine-1-carbonyl]-5-methylbenzoyl]amino]propyl]piperazine-1-carboxylate
  参考文献：
  名称：

  Piperazine sulfonamide BACE1 inhibitors: Design, synthesis, and in vivo characterization

  摘要：

  With collaboration between chemistry, X-ray crystallography, and molecular modeling, we designed and synthesized a series of novel piperazine sulfonamide BACE1 inhibitors. Iterative exploration of the non-prime side and S2' sub-pocket of the enzyme culminated in identification of an analog that potently lowers peripheral A beta(40) in transgenic mice with a single subcutaneous dose. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.03.050

文献信息

• Highly Selective and Potent Human β‐Secretase 2 (BACE2) Inhibitors against Type 2 Diabetes: Design, Synthesis, X‐ray Structure and Structure–Activity Relationship Studies
  作者：Arun K. Ghosh、Margherita Brindisi、Yu‐Chen Yen、Emma K. Lendy、Satish Kovela、Emilio Leal Cárdenas、Bhavanam Sekhara Reddy、Kalapala Venketeswara Rao、Deborah Downs、Xiangping Huang、Jordan Tang、Andrew D. Mesecar

  DOI：10.1002/cmdc.201800725

  日期：——

  was determined. Based on this structure, a computational docking study was performed which led to inhibitor 2 a-bound BACE2 models. These were used to optimize the potency and selectivity of inhibitors. A systematic structure-activity relationship study led to the identification of determinants of the inhibitors' potency and selectivity toward the BACE2 enzyme. Inhibitors 2 d [N3 -[(1S,2R)-1-benzyl-2-hydroxy-3-[[(1S

  本文中，我们介绍了有效的和高度选择性的β-分泌酶2（memapsin 1，β位淀粉样蛋白前体蛋白裂解酶2或BACE 2）抑制剂的设计，合成和生物学评估。BACE2被公认为是2型糖尿病激动人心的新靶标。BACE1的X射线结构与抑制剂2 a N3-[（1S，2R）-1-苄基-2-羟基-3-[[（1S，2S）-2-羟基-1-（异丁基氨基甲酰基）丙基测定了含有羟乙胺等排异构体的[氨基]丙基] -5- [甲基（甲基磺酰基）氨基] -N1-[（（1R）-1-苯基丙基]苯-1,3-二甲酰胺）。基于该结构，进行了计算对接研究，其导致了抑制剂2a-结合的BACE2模型。这些用于优化抑制剂的效力和选择性。一项系统的结构-活性关系研究导致确定抑制剂对BACE2酶的效力和选择性的决定因素。抑制剂2 d [N3-[（1S，2R）-1-苄基-2-羟基-3-[[（1S，2S）-2-羟基-1-（异丁基氨基甲酰基）戊基]氨基]丙基]
• CYCLIC AMINE BACE-1 INHIBITORS HAVING A BENZAMIDE SUBSTITUENT
  申请人：Cumming Jared N.

  公开号：US20100152138A1

  公开（公告）日：2010-06-17

  Disclosed are compounds of the formula or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is R is —C(O)—N(R 27 )(R 28 ) or and the remaining variables are as defined in the specification. Also disclosed are pharmaceutical compositions comprising the compounds of formula I. Also disclosed are methods of treating cognitive or neurodegenerative diseases such as Alzheimer's disease. Also disclosed are pharmaceutical compositions and methods of treating cognitive or neurodegenerative diseases comprising the compounds of formula I in combination with a β-secretase inhibitor other than those of formula I, an HMG-CoA reductase inhibitor, a gamma-secretase inhibitor, a non-steroidal anti-inflammatory agent, an N-methyl-D-aspartate receptor antagonist, a cholinesterase inhibitor or an anti-amyloid antibody.

  本发明揭示了式I的化合物，或其药学上可接受的盐或溶剂，其中R1是R是—C（O）—N（R27）（R28）或，其余变量如规范中所定义。本发明还揭示了包括式I化合物的药物组成物。本发明还揭示了治疗认知或神经退行性疾病，如阿尔茨海默病的方法。本发明还揭示了包括式I化合物的药物组成物和治疗认知或神经退行性疾病的方法，其中该组成物与β-分泌酶抑制剂（非式I的）、HMG-CoA还原酶抑制剂、γ-分泌酶抑制剂、非甾体抗炎药、N-甲基-D-天门冬氨酸受体拮抗剂、胆碱酯酶抑制剂或抗淀粉样蛋白抗体结合使用。
• CYCLIC AMIDE BACE-1 INHIBITORS HAVING A BENZAMIDE SUBSTITUENT
  申请人：Pharmacopeia Drug Discovery, Inc.

  公开号：US20140128361A1

  公开（公告）日：2014-05-08

  Disclosed are compounds of the formula or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is R is —C(O)—N(R 27 )(R 28 ) or and the remaining variables are as defined in the specification. Also disclosed are pharmaceutical compositions comprising the compounds of formula I. Also disclosed are methods of treating cognitive or neurodegenerative diseases such as Alzheimer's disease. Also disclosed are pharmaceutical compositions and methods of treating cognitive or neurodegenerative diseases comprising the compounds of formula I in combination with a β-secretase inhibitor other than those of formula I, an HMG-CoA reductase inhibitor, a gamma-secretase inhibitor, a non-steroidal anti-inflammatory agent, an N-methyl-D-aspartate receptor antagonist, a cholinesterase inhibitor or an anti-amyloid antibody.

  本发明涉及以下公式的化合物，或其药学上可接受的盐或溶剂： 其中，R1是R为—C（O）—N（R27）（R28）或 其余变量如规范中所定义。 本发明还涉及包括公式I化合物的制药组合物。 本发明还涉及治疗认知或神经退行性疾病（如阿尔茨海默病）的方法。 本发明还涉及包括公式I化合物与β-分泌酶抑制剂、HMG-CoA还原酶抑制剂、γ-分泌酶抑制剂、非甾体抗炎药、N-甲基-D-天门冬氨酸受体拮抗剂、胆碱酯酶抑制剂或抗淀粉样蛋白抗体组合的治疗认知或神经退行性疾病的制药组合物和方法。
• Rational design of novel, potent piperazinone and imidazolidinone BACE1 inhibitors
  作者：J.N. Cumming、T.X. Le、S. Babu、C. Carroll、X. Chen、L. Favreau、P. Gaspari、T. Guo、D.W. Hobbs、Y. Huang、U. Iserloh、M.E. Kennedy、R. Kuvelkar、G. Li、J. Lowrie、N.A. McHugh、L. Ozgur、J. Pan、E.M. Parker、K. Saionz、A.W. Stamford、C. Strickland、D. Tadesse、J. Voigt、L. Wang、Y. Wu、L. Zhang、Q. Zhang

  DOI：10.1016/j.bmcl.2008.04.050

  日期：2008.6

  Guided by structure-based design, we synthesized two novel series of potent inhibitors of BACE1 and generated extensive SAR around both the prime and non-prime side binding pockets. The key feature of both series is a cyclic amine motif specifically crafted to achieve interactions with both the flap and with the S2' pocket.
• [EN] CYCLIC AMINE BACE-1 INHIBITORS HAVING A BENZAMIDE SUBSTITUENT<br/>[FR] INHIBITEURS BACE-1 AMINES CYCLIQUES A SUBSTITUANT BENZAMIDE
  申请人：SCHERING CORP

  公开号：WO2005016876A3

  公开（公告）日：2005-09-22